Interactive Narrative Gap Audit Example
Click Around to uncover where the story breaks.
Messaging Gap Audit · Constructed Example
Three functions.
Three versions of the same drug.
Meridian Therapeutics · MRD-471 · Treatment-resistant MDD · Phase III Upcoming: Type B meeting with FDA · Series C close · Q3 partnering conference
This is a constructed example. Meridian Therapeutics and MRD-471 are fictional. The gaps shown reflect patterns observed across pre-commercial biotech companies preparing for advisory boards, Series C raises, and partner meetings.
What each function says about MRD-471
Select any underlined phrase to see the gap it creates. All three documents describe the same drug.
"MRD-471 is a novel serotonin-norepinephrine reuptake modulator being evaluated for efficacy and safety in adult patients with treatment-resistant major depressive disorder, defined as inadequate response to two or more antidepressant regimens of adequate dose and duration . The primary endpoint is change from baseline in MADRS total score at Week 8 . Secondary endpoints include response rate (≥50% reduction in MADRS), remission rate (MADRS ≤10), and durability of response through Week 24 ."
Defines TR-MDD by treatment history, not disease biology. This is a regulatory anchor, not a commercial story. Commercial is already using a different patient definition.
Primary endpoint is symptom scale change. Commercial is leading with "rapid onset within 72 hours" — a claim unanchored to this registered endpoint.
24-week durability is a secondary endpoint here. Medical Affairs is building the entire differentiation story on an exploratory anhedonia subgroup, not on this registered outcome.
"MRD-471 addresses a $14 billion market opportunity in patients who have failed standard-of-care antidepressants. In clinical studies, MRD-471 demonstrated rapid onset of action within 72 hours and a favorable tolerability profile compared to existing therapies. Meridian believes MRD-471 has the potential to become a first-line option for patients with difficult-to-treat depression , transforming the treatment paradigm for millions of Americans living with this debilitating condition."
Rapid onset within 72 hours is not a registered endpoint. If a partner asks which trial result supports this claim, no one from Clinical or Regulatory can point to it.
The trial defines a TR-MDD population that has failed at least two regimens. "First-line option" contradicts the protocol definition of every patient enrolled in the study.
Mechanistic overclaim not supported by Phase III data. This is the sentence a KOL will push back on in public. It also puts Regulatory in an impossible position before the Type B meeting.
"MRD-471 offers a differentiated mechanism of action targeting both serotonergic and noradrenergic pathways, with emerging data suggesting particular benefit in patients with anhedonia as a predominant symptom cluster . The medical team is focused on building scientific exchange around the anhedonia subpopulation analysis ahead of the upcoming advisory board. We believe this subpopulation data, if confirmed, could reframe how clinicians think about patient selection for MRD-471 . If confirmed , this signal could meaningfully change the label conversation."
A subgroup exploratory analysis is being positioned as the differentiation story. The registered primary endpoint is MADRS change. These are not the same argument, and they lead to different advisory board conversations.
This implies a different patient population than Clinical registered or Commercial is pitching. Three functions, three patient definitions. A KOL will notice within the first ten minutes.
"If confirmed" signals the data is exploratory. Commercial's press release communicates certainty. This contradiction lives in the same company's external documents, readable side by side.
Failed ≥2 adequate antidepressant courses (TR-MDD per protocol definition)
Anyone with difficult-to-treat depression, potentially including first-line candidates
TR-MDD patients with anhedonia as the dominant symptom cluster
Reduces MADRS score by Week 8. Durability through Week 24 as a secondary outcome.
Rapid onset within 72 hours. Favorable tolerability vs. existing therapies.
Dual serotonergic-noradrenergic mechanism. Anhedonia subpopulation benefit (exploratory).
Not stated. The protocol defines endpoints, not differentiation.
Speed of onset. Tolerability versus existing standard of care.
Mechanism of action. Anhedonia signal (not yet confirmed in the data).
The gaps above took three minutes to find. They exist because Clinical, Commercial, and Medical Affairs are each right about their piece of the story. The problem is that no one has built the version that holds across all three.